112. Cooper PD, Steele EJ. Algammulin, a new vaccine adjuvant comprising gamma inulin particles containing alum: preparation
and in vitro properties. Vaccine 1991;9:351–357.
113. Cooper PD, Steele EJ. The adjuvanticity of gamma inulin. Immunol Cell Biol 1988 66;( Pt 5–6):345–352.
114. Frazer I, Tindle R, Fernando G, Malcolm K, Herd K, McFadyn S, et al. Safety and immunogenicity of HPV16 E7/Algammulin.
In T. RW, editor Vaccines for Human Papillomavirus Infection and Anogenital Disease. New York: RG Landes 1999;p. 91–104
115. Brewer JM. (How) do aluminium adjuvants work? Immunol Lett 2006;102:10–15.
116. Goldenthal KL, Cavagnaro JA, Alving CR, Vogel FR. Safety evaluation of vaccine adjuvants. National Cooperative Vaccine
Development Working Group. AIDS Res Hum Retroviruses 1993;9:S45–S49.
117. Hunter RL. Overview of vaccine adjuvants: present and future. Vaccine 2002;20 Suppl 3:S7–12.
118. Lindblad EB. Aluminium adjuvants—in retrospect and prospect. Vaccine 2004 22:3658–3668.
119. Moingeon P, Haensler J, Lindberg A. Towards the rational design of Th1 adjuvants. Vaccine 2001;19:4363–4372.
120. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005;11:S63–68.
121. Pink JR, Kieny MP. 4th meeting on novel adjuvants currently in/close to human clinical testing world health organization
— organisation Mondiale de la Sante Fondation Merieux, Annecy, France, 23–25, June 2003. Vaccine 2004;22:2097–2102.
122. Seya T, Akazawa T, Tsujita T, Matsumoto M. Role of Toll-like receptors in adjuvant-augmented immune therapies. Evid Based
Complement Alternat Med 2006;3:31–38; discussion 133–137.
123. Stills Jr., HF. Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants.
Ilar J 2005;46:280–293.
124. Tomai MA, Johnson AG. T cell and interferon-gamma involvement in the adjuvant action of a detoxified endotoxin. J Biol
Response Mod 1989;8:625–643.
125. Vogel, FP, MF. A summary compendium of vaccine adjuvants and excipients. In: N.M. Powell MF, editor. Vaccine design:
the subunit and adjuvant approach. New York: Plenum Publishing Corporation; 1995;p. 234–250
126. Vogel FR. Adjuvants in perspective. In: Brown, FH, editor. Modulation of the immune response to vaccine antigens. Karger;
1998.
127. Warren HSC. Future prospects for vaccine adjuvants. Crit Rev Immunol 1986;4:369–388.
|
